Lepu Medical(SZ:300003) Chan Ye Xin Xi Wang·2025-09-26 01:20Group 1 - The core viewpoint of the article highlights the significant growth and clinical value of thromboelastography (TEG) devices in China, with a projected market size increase from 298 million yuan in 2018 to 965 million yuan by 2024, reflecting a compound annual growth rate (CAGR) of 21.7% [1][8][11] - TEG devices are crucial for dynamic monitoring of coagulation and fibrinolysis processes, providing insights that traditional coagulation tests cannot offer, thus enhancing patient management in various clinical settings [1][7][8] - The market for TEG devices is characterized by a shift towards fully automated systems, which are expected to grow significantly, with a market size of 187 million yuan in 2024, representing a year-on-year growth of 33.3% [1][9][11] Group 2 - The TEG device market in China is dominated by semi-automated models, which accounted for 81% of the market share in 2024, while the supply of TEG products is expanding, with over 50 registered devices from more than 30 companies as of September 2025 [1][9][10] - The competitive landscape is shifting, with domestic brands like Maiketian, Heanshi, Lepu, Baorui, and Jianlang capturing over 80% of the market share, indicating a high concentration in the industry [1][10] - The future of the TEG market is promising, with expectations of exceeding 2 billion yuan by 2029, driven by an aging population, increasing prevalence of cardiovascular diseases, and advancements in diagnostic technologies [1][11][12]